Fasting Hormone Pathway for Healthspan

Inside the Fasting Body: A New Hormone Pathway for Healthspan

For decades, caloric restriction and intermittent fasting have stood as pillars of longevity research, linked to longer, healthier lives in animals. The promise for humans has been compelling but mechanistically vague. New research is changing that. Two 2026 studies provide a clearer picture of how fasting might work, identifying a specific hormone-activated pathway that improves healthspan and offering a tempered, evidence-based perspective on its current utility for metabolic health.

A Defined Molecular Circuit for Fasting Benefits

The study from the University of California, San Francisco, moves beyond broad observations to a precise mechanism. Using the worm C. elegans, researchers led by A. Guijarro-Hernández and K. Ashrafi found that fasting and caloric restriction trigger the production of a steroid hormone called 5-androstene-3β,17β-diol (ADIOL). This molecule binds to and activates a receptor named NHR-91.

This ADIOL-NHR-91 axis initiates a cascade that lowers levels of a brain metabolite called kynurenic acid. Disrupting this pathway—by blocking ADIOL synthesis or removing the NHR-91 receptor—completely eliminated the healthspan benefits of dietary restriction. The worms did not move better or resist stress as they aged. Crucially, this pathway operated separately from lifespan; ADIOL activation made the worms healthier in their lifetime but did not make them live longer. This finding challenges the assumption that healthspan and lifespan extensions are always coupled.

Human Application: Promise, Pause, and Practical Paths

Parallel work from the University of Pittsburgh, led by Matthew L. Steinhauser and Pouneh K. Fazeli, grounds this molecular excitement in clinical reality. Their analysis confirms that while humans possess “evolutionary adaptations” for surviving periods without food, the jump to prescribing fasting for longevity is premature. The evidence for widespread benefit is not yet sufficient.

They propose a focused application. For the motivated patient who is overweight or obese and lacks specific risk factors like frailty or a history of eating disorders, a trial of intermittent fasting or time-restricted eating is a reasonable strategy for improving metabolic health. The goal here is not necessarily longevity but managing weight and metabolic parameters. They argue future studies must incorporate deep molecular profiling (“multi-omics”) in humans to understand if pathways like the ADIOL axis are activated in us, which could lead to targeted therapies that mimic fasting without the dietary hardship.

Separating Healthspan from Lifespan

The UCSF finding that ADIOL improves healthspan without extending lifespan is a critical nuance for the field. It suggests the biological goal of fasting regimens might be more accurately described as compression of morbidity—staying healthier for a greater proportion of one’s life—rather than simply prolonging it. This distinction is vital for setting realistic public expectations and for guiding research. Scientists can now search for interventions that specifically modulate this ADIOL-kynurenic acid pathway, potentially decoupling the challenge of fasting from its benefits.

This aligns with the Pittsburgh team’s perspective. Their review suggests the primary proven benefit of fasting in humans currently sits in the realm of metabolic improvement, a key component of healthspan. They caution that “the current state of evidence is limited and not sufficient to justify widespread adoption of fasting practices,” but also admit it is “not sufficient to exclude the possibility that fasting holds a key to a longer life.”

The Future: From Fasting to Fasting Mimetics

The convergence of these studies points to a clear future direction. The discovery of defined pathways like ADIOL-NHR-91 provides specific molecular targets. The next step is to confirm this biology in mammals and humans, a process that requires the detailed, mechanistic human trials called for by Steinhauser and Fazeli.

The ultimate goal is not to convince everyone to fast. It is to understand the beneficial signals fasting produces so thoroughly that we can develop “fasting mimetic” drugs or supplements. These agents would provide the healthspan and metabolic benefits of caloric restriction—potentially via the ADIOL pathway or others—without requiring persistent hunger or major dietary change. This transition from broad behavioral intervention to precise molecular medicine represents the next frontier in longevity science.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42043665/
https://pubmed.ncbi.nlm.nih.gov/42021510/